CMB International Leads $100M Series B Round Into US Biopharmaceutical Firm

Login to View

U.S. biopharmaceutical company Apollomics, Inc., has raised US$100 million in a series B financing round, led by CMB International (CMBI), a subsidiary of China Merchants Bank. The round was also participated in by existing series A round investor, OrbiMed Asia, according to an announcement today. 

Continue reading with a China Money Network subscription

Join Now

Already have an account or paid subscription? Log in